Johnson & Johnson delivered strong first-quarter results with a 29.1% increase in net earnings and solid operational sales growth, despite challenges from generic competition and healthcare reform. Management's optimistic guidance and growth in key segments like medical devices and international markets suggest a positive short-term outlook for the stock.

[1]